Portfolio company Regenosine receives a $1.67M NIH NIAMS Phase II SBIR grant
November 9, 2021
Congratulations to portfolio company Regenosine on receiving a $1.67M NIH NIAMS Phase II SBIR grant to commercially develop their disease modifying osteoarthritis drug. Read More
